Viatris Innovation GmbH
Allschwil, Switzerland
Bruno Flamion, MD/PhD, a Belgian national, with clinical experience in internal medicine and nephrology, is now SVP, Head Strategic Development in Viatris Innovation in Allschwil, Switzerland (since April 2025). He held a similar position in Actelion and Idorsia Pharmaceuticals from 2016 to 2025. Prior to that, he was Full Professor of Physiology and Clinical Pharmacology in the Faculty of Medicine of the University of Namur, Belgium, for 26 years, from 1996 to 2022, as well as Dean of the Faculty of Medicine (2003-2005) and Head of the Department of Medicine (2005-2008). He also worked part-time for the European Medicines Agency (EMA), London, UK, for 12 years (2000-2012), as a member of CHMP (the main decision committee) and CAT (Committee for Advanced Therapies) representing Belgium, chair of the Pharmacokinetics Group, and, most importantly, chair of the Scientific Advice Working Party for 6 years (2005-2010). Earlier, he was Research Associate at the National Institutes of Health (NIH), Bethesda, MD, USA (1988-1992), and at the Belgian National Fund for Scientific Research (1992-1996).
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Idorsia Pharmaceuticals: Employee (Terminated, March 31, 2025), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, March 31, 2025); Viatris Innovation GmbH: Employee (Ongoing)
